Overview of the Phase I study with acalabrutinib (ACP-196) in CLL

Overview of the Phase I study with acalabrutinib (ACP-196) in CLL

VJHemOnc

4 years
292 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Jacqueline Barrientos, MD, discusses the drug acalabrutinib (ACP-196), a second generation Bruton's tirosine kinase (BTK) inhibitor that demonstrates reduced off-target effects. Dr Barrientos provides an overview of the Phase I study, where 96% of patients responded to treatment, including patients that have been through partial remission with lymphocytosis.
Up Next Autoplay